The role of CYP2C9 gene polymorphism in rheumatoid arthritis

CYP2C9 polymorphism in rheumatoid arthritis



CYP2C9, polymorphism, rheumatoid arthritis


Background/Aim: The inflammatory disorder rheumatoid arthritis (RA) affects quality of life and worsens with symptoms in the extra-articular tissues and systemic joints. The most significant member of the Cytochrome P450 enzyme family, Cytochrome P450 2C9 (CYP2C9), plays an essential role in the alkylation, demethylation, and hydroxylation of a variety of substances. Insufficient studies as to whether the susceptibility to rheumatoid arthritis is genetic exists. Therefore, our study presents new information on whether CYPC9 is a genetic risk factor. In this study, we sought to determine whether rheumatoid arthritis and the CYP2C9 gene polymorphism are related.

Methods: This study was conducted as a prospective case-control study. Fifty patients with RA and 50 healthy individuals were included in our study group. Blood from the controls and patients was drawn into ethylenediaminetetraacetic acid (EDTA)-containing tubes, and using a DNA isolation kit, DNA was isolated from leukocytes. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to assess the genotypes of CYPC9*2 and CYP2C9*3 with the LightCycler-CYP2C9 mutation detection kit.

Results: The heterozygous CYP2C9*2 genotype was found to carry a 2.85-fold risk when compared with the controls (odds ratio [OR]=2.85, 95% confidence interval [CI]: 0.52–15.50; P=0.22); however, this risk was not statistically significant. It was found that people with the CYP2C9*3 heterozygous genotype had a statistically significant 2.79-fold higher risk compared to the controls (OR=2.79, 95% CI: 1.13–7.00 P=0.04).

Conclusion: The heterozygous genotype of CYP2C9*3 may contribute to the onset of RA.


Download data is not yet available.


Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019;170(1):ITC1-ITC16. doi: 10.7326/AITC201901010. DOI:

Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-39. doi: 10.1002/acr.24596. DOI:

Croia C, Bursi R, Sutera D, Petrelli F, Alunno A, Puxeddu I. One year in review 2019: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):347-57. PMID: 31111823.

Van Doornum S, Brand C, King B, Sundararajan V. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2061-8. doi: 10.1002/art.21932 DOI:

Sánchez-Maldonado JM, Cáliz R, Canet L, Horst RT, Bakker O, den Broeder AA, et al. Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium. Sci Rep. 2019;9(1):14812. doi: 10.1038/s41598-019-51255-0. DOI:

Waring RH. Cytochrome P450: genotype to phenotype. Xenobiotica. 2020;20(1):9-18. doi: 10.1080/00498254.2019. DOI:

Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, et al. PharmVar GeneFocus: CYP2C9.Clin Pharmacol Ther. 2021;110(3):662-76. doi: 10.1002/cpt.2333 DOI:

Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003;35:99–106. doi: 10.1081/dmr-120023681 DOI:

Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes. Curr Drug Metab. 2009;10(6):567-78. doi: 10.2174/138920009789375397 DOI:

Wysocki T, Olesińska M, Paradowska-Gorycka A. Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to Clinical Practice. Cells. 2020;2;9(5):1127. doi: 10.3390/cells9051127 DOI:

Smallwood MJ, Nissim A, Knight AR, Whiteman M, Haigh R, Winyard PG. Oxidative stress in autoimmune rheumatic diseases Free Radic Biol Med. 2018;125:3-14. doi: 10.1016/j.freeradbiomed.2018.05.086. DOI:

Phull AR, Nasir B, Haq IU, Kim SJ. Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid arthritis. Chem Biol Interact. 2018;1;281:121-36. doi: 10.1016/j.cbi.2017.12.024 DOI:

Hoxha M, Zappacosta B. CYP-derived eicosanoids: Implications for rheumatoid arthritis. Prostaglandins Other Lipid Mediat. 2020;146:106405. doi: 10.1016/j.prostaglandins.2019.106405 DOI:

Blake DR, Merry P, Unsworth J, Kidd BI, Outhwaite JM, Ballard R. Hypoxia reperfusion injury in the inflamed human joint. Lancet. 1989;i:289–93. doi: 10.1016/s0140-6736(89)91305-6. DOI:

Layton MA, Jones PW, Alldersea JE, Strange RC, Fryer AA, Dawes PT, Mattey DL. The therapeutic response to D-penicillamine in rheumatoid arthritis: influence of glutathione S-transferase polymorphisms. Rheumatology (Oxford). 1999;38(1):43-7. doi: 10.1093/rheumatology/38.1.43 DOI:

Von Schmiedeberg S, Fritsche E, Ro¨nnau AC, Specker C, Golka K, Richter-Hintz D, Schuppe HC, Lehmann P, Ruzicka T, Esser C, Abel J, Gleichmann E. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol. 1999;455:147. doi: 10.1007/978-1-4615-4857-721. DOI:

Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med. 1995;73:539. doi: 10.2165/00003088-200645010-00002 DOI:

Halliwell B. Oxygen radicals, nitric oxide and human inflammatory joint disease. Ann Rheum Dis. 1995;54:505-10. doi: 10.1136/ard.54.6.505 DOI:

Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol. 2005;4:391-407. doi: 10.1021/tx00022a001 DOI:

Morinobu S, Morinobu A, Kanagawa S, Hayashi N, Nishimura K, Kumagai S. Glutathione S-transferase M1, T1, and P1 genotypes in Japanese patients with rheumatoid arthritis. J Rheumatol. 2006;24(3):268-73. PMID: 16870093

Yen JH, Chen CJ, Tsai WC, Lin CH, Ou TT, Hu CJ, Liu HW. Manganese Superoxide Dismutase and Cytochrome P450 1A1 Genes Polymorphisms in Rheumatoid Arthritis in Taiwan. Hum Immunol. 2003;64(3):366-73. doi: 10.1016/s0198-8859(02)00818-2. DOI:

Pawlik A, Ostanek L, Brzosko I, Gawroska-Szklarz B, Brzosko M, Dabrowska-Zamojcin E. Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2002;72(3):319-25. 10.1067/mcp.2002.126740 DOI:

Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, et al. Sitokrom P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010;20(4):277-81. doi: 10.1097/FPC.0b013e3283349e84. DOI:






Research Article

How to Cite

Yıldırım Yaroğlu H, Biçer A. The role of CYP2C9 gene polymorphism in rheumatoid arthritis: CYP2C9 polymorphism in rheumatoid arthritis. J Surg Med [Internet]. 2023 Oct. 10 [cited 2024 Jul. 15];7(10):665-8. Available from: